Page last updated: 2024-12-06
propildazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
propildazine: RN given refers to parent cpd; synonym ISF 2123 refers to di-HCl; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 68829 |
| CHEMBL ID | 2107172 |
| CHEBI ID | 134858 |
| SCHEMBL ID | 309115 |
| MeSH ID | M0055145 |
Synonyms (30)
| Synonym |
|---|
| 3-hydrazino-6-((2-hydroxypropyl)methylamino)pyridazine dihydrochloride |
| ccris 5384 |
| 3(2h)-pyridazinone, 6-((2-hydroxypropyl)methylamino)-, hydrazone |
| pildralazine [inn] |
| (+-)-1-((6-hydrazino-3-pyridazinyl)methylamino)-2-propanol |
| brn 0649354 |
| pildralazina [spanish] |
| pildralazinum [latin] |
| pildralazine |
| propildazine |
| propyldazine |
| CHEBI:134858 |
| 1-[(6-hydrazinylpyridazin-3-yl)-methylamino]propan-2-ol |
| AKOS006273428 |
| CHEMBL2107172 |
| 64000-73-3 |
| unii-fu2bgc781u |
| 5-25-18-00060 (beilstein handbook reference) |
| pildralazina |
| pildralazinum |
| fu2bgc781u , |
| SCHEMBL309115 |
| (+/-)-1-((6-hydrazino-3-pyridazinyl)methylamino)-2-propanol |
| pildralazine [mi] |
| DTXSID7043746 |
| 3-hydrazino-6-[(2-hydroxypropyl)-methylamino]-pyridazin |
| Q7193849 |
| CS-0025881 |
| HY-106471 |
| 1-((6-hydrazinylpyridazin-3-yl)(methyl)amino)propan-2-ol |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "42 mg/kg) on heart rate, arterial blood pressure and plasma renin activity (PRA) was compared with the effect of the substance after treatment at the same respective dosage twice daily over 4 days." | ( Altered blood pressure response to propyldazine after repeated oral administration in conscious normotensive dogs: role of the renin-angiotensin system. Bacher, S; Beck, A; Kraupp, O; Raberger, G; Seitelberger, R, ) | 0.13 |
| " Pyd action is modified only by the most active purine 2-Cl-adenosine, which displaces the dose-response curves to the right." | ( Interactions between hydralazine, propildazine and purines on arterial smooth muscle. Chevillard, C; Saiag, B; Worcel, M, 1981) | 0.54 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| dialkylarylamine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 12 (85.71) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||